ライフサイエンスコーパス: HIV seroconversion

1 ase of suicidal attempt in a woman following HIV seroconversion.

2 ytokine concentrations associated with later HIV seroconversion.

3 27, p<0.0001) in the past 6 months predicted HIV seroconversion.

4 n were reconstructed from estimated dates of HIV seroconversion.

5 in which gel users are closely monitored for HIV seroconversion.

6 imilar to the longitudinal estimate based on HIV seroconversion.

7 tic cell density, which potentially mediates HIV seroconversion.

8 d to estimate adjusted odds ratios (aORs) of HIV seroconversion.

9 The primary outcome was time to HIV seroconversion.

10 sessed how this risk changes with time since HIV seroconversion.

11 per patient were done retrospectively after HIV seroconversion.

12 en prevalent or incident HSV-2 infection and HIV seroconversion.

13 Documentation of recent HIV seroconversion.

14 up was withdrawn at the 6-month visit due to HIV seroconversion.

15 nce estimate based on prospectively observed HIV seroconversions.

16 phic factors to predict the one-year risk of HIV seroconversion: (1) membership in >=1 known "Risk Gr

17 At 10 years since HIV seroconversion, 283 individuals had LTNP, of whom 20

18 and any detectable HPV at the visit prior to HIV seroconversion (adjusted odds ratio, 1.02; 95% confi

19 sition was not significantly associated with HIV seroconversion, after adjustment for sexual behavior

20 lts suggest an independent increased risk of HIV seroconversion among HPV-positive men.

21 HBV seroconversion predicted subsequent HIV seroconversion among male IDUs (relative incidence [

22 was observed in the first 5 years following HIV seroconversion among those infected sexually, though

23 Data on human immunodeficiency virus (HIV) seroconversion among men who have sex with men (MSM

24 ed long-term progression-free survival after HIV seroconversion and aimed to identify factors associa

25 HPV clearance was associated with subsequent HIV seroconversion and also with increased epidermal den

26 This study aimed to document HIV seroconversion and associated determinants, PrEP adh

27 Identical predictors of HIV seroconversion and death included residence in south

28 HIV seroconversion and inflammation could increase the r

29 ty to reach persons who are at high risk for HIV seroconversion and provide them with evaluation, tre

30 lled in the present study within 6 months of HIV seroconversion and self-selected whether to initiate

31 use of BED-CEIA for the detection of recent HIV seroconversion and the calculation of incidence esti

32 incidence and mortality using the number of HIV seroconversions and deaths, respectively, divided by

33 of acute HIV infection, (2) documentation of HIV seroconversion, and (3) detection of recent HIV infe

34 HCV RNA load stabilized at 4 years after HIV seroconversion, and this point was used for analysis

35 omen's Interagency HIV Study who experienced HIV seroconversion, and used these data to characterize

36 clearance was significantly associated with HIV seroconversion (aOR, 3.25 [95% confidence interval {

37 have sex with men showed fair prediction of HIV seroconversion (AUC, 0.701).

38 al among HIV-positive men 5 to 6 years after HIV seroconversion, but not at 12 to 18 months, and the

39 IV status and TB was estimated by time since HIV seroconversion, calendar period, and age.

40 Samples from 213 women who experienced HIV seroconversion (cases) during a longitudinal study i

41 h an estimated human immunodeficiency virus (HIV) seroconversion date, viral suppression <=400 copies

42 ected injection drug users (IDUs) with known HIV seroconversion dates from four cohort studies were p

43 portance of assessing the genetic linkage of HIV seroconversion events in HIV prevention studies invo

44 inguish recent human immunodeficiency virus (HIV) seroconversion from long-term infections.

45 Dates of HIV seroconversion had been estimated for all patients,

46 l counts after human immunodeficiency virus (HIV) seroconversion have decreased over calendar time am

47 ated risks for human immunodeficiency virus (HIV) seroconversion; however, others have reported highe

48 um specimens were selected with reference to HIV seroconversion: (i) more than 2 years prior, (ii) le

49 ulatory care clinics in Italy, with observed HIV seroconversion in 1980-1988.

50 bserved a trend toward lower d(N)/d(S) after HIV seroconversion in 7 of 10 subjects and lower d(N)/d(

51 At HIV seroconversion in 8 of 15 patients, a 30-bp deletion

52 SETTING, AND POPULATION: Mortality following HIV seroconversion in a large multinational collaboratio

53 ith the MAA to the annual incidence based on HIV seroconversion in a longitudinal cohort.

54 dy was conducted to examine risk factors for HIV seroconversion in homosexual men who became infected

55 entify a trend of lower CD4 counts following HIV seroconversion in Italy and suggest indirectly that

56 Independent predictors of HIV seroconversion in multivariable pooled logistic regr

57 The main outcome of this study was HIV seroconversion in the intent-to-treat population as

58 We observed 1619 HIV seroconversions in 17 016 individuals, over 60 349 p

59 after on-site PrEP access, compared with 133 HIV seroconversions in 2860 person-years (4.65%) before

60 ticipants with human immunodeficiency virus (HIV) seroconversion in The Ring Study, a phase 3 trial o

61 Most human immunodeficiency virus (HIV) seroconversions in people who have initiated preexp

62 tive incidence 53% [95% CI: 43%, 62%]) and 1 HIV-seroconversion in a non-pregnant woman.

63 Median age of HIV seroconversion increased by 5.5 y in men and 3.0 y i

64 The odds of HIV seroconversion increased with increasing number of H

65 lored despite being Bacteria Associated with HIV Seroconversion, Inflammation, and immune Cells (BASI

66 nd the risk of human immunodeficiency virus (HIV) seroconversion is unclear, and the genital cellular

67 HIV seroconversions mainly occurred in participants who

68 raphic factors to predict the 1-year risk of HIV seroconversion: membership in >=1 known "risk group"

69 th Poisson regression to model predictors of HIV seroconversion, models that included measures of NEP

70 Few HIV seroconversions (n = 10) precluded our ability to as

71 Thirty-three HIV seroconversions occurred over 4,618.9 person-years (

72 Eight HIV seroconversions occurred overall, with four document

73 tion was 17.2 cases per 100 person years; no HIV seroconversions occurred.

74 ction was detected in 85 percent of men with HIV seroconversion on the basis of the presence of E2 an

75 of 0.45 logs, increasing by 0.60 logs after HIV seroconversion (P < .0001), by 0.12 logs each subseq

76 igher HIV RNA levels in the first year after HIV seroconversion (P=.88) or faster rates of increase o

77 reening or confirmatory tests using an acute HIV seroconversion panel.

78 ase chain reaction (RT-PCR) assays in 3 of 5 HIV seroconversion panels.

79 n models were used to identify predictors of HIV seroconversion (primary outcome) or death.

80 The HIV seroconversion rate was 6.4 (95% CI: 1.3-18.7) per 1

81 We calculated HIV seroconversion rates (using the midpoint between the

82 In contrast, HIV seroconversion rates varied little from the overall

83 We assessed associations between HIV seroconversion risk and several factors with Cox reg

84 ces by geographical origin (GO) in time from HIV seroconversion (SC) to AIDS, death, and initiation o

85 thm for recent human immunodeficiency virus (HIV) seroconversion (STARHS) distinguishes between recen

86 ing a serologic testing algorithm for recent HIV seroconversion that uses both a sensitive and a less

87 tients was also evaluated 5 to 6 years after HIV seroconversion (the late visit).

88 PrEP effectiveness should account for HIV seroconversion, the variable risk of HIV infection (

89 We estimated the time from HIV seroconversion to ART initiation in a population-bas

90 panels from 155 persons identified prior to HIV seroconversion to assess antibody-based methods for

91 the time from human immunodeficiency virus (HIV) seroconversion to antiretroviral therapy (ART) init

92 In a cohort study, annual incidence based on HIV seroconversion was 1.04% (95% CI, .70%-1.55%).

93 2 weeks and 6 months after (early treatment) HIV seroconversion was associated with improvements in t

94 HIV seroconversion was associated with raised genital in

95 the loss of GBV-C RNA by 5 to 6 years after HIV seroconversion was associated with the poorest progn

96 HIV incidence based on HIV seroconversion was calculated as number of events/10

97 nalyzed samples were from the visit in which HIV seroconversion was detected and the visit preceding

98 Using stored serum, the precise timing of HIV seroconversion was determined and the early effects

99 GBV-C status 12 to 18 months after HIV seroconversion was not significantly associated with

100 No HIV seroconversion was reported during the 206 person-ye

101 en early after human immunodeficiency virus (HIV) seroconversion was investigated in a cohort of 96 m

102 For the primary outcome (time to HIV seroconversion) we analysed 3011 women in the Carrag

103 er, men without GBV-C RNA 5 to 6 years after HIV seroconversion were 2.78 times as likely to die as m

104 HIV seroconversions were defined as a positive HIV test

105 In addition, no HIV seroconversions were detected among prison inmates.

106 No other HIV seroconversions were identified during the study.

107 A total of 12 HIV seroconversions were observed in 556 person-years (i

108 A total of 46 HIV seroconversions were observed in 919 person-years wi

109 No HIV seroconversions were observed over the follow-up per

110 Of these, 145 HIV seroconversions were observed, resulting in a weight